1. Thoft RA. Conjunctival transplantation.
Arch Ophthalmol 1977;95:1425-1427.
2. Kwitko S, Marinho D, Barcaro S, et al. Allograft conjunctival transplantation for bilateral ocular surface disorders.
Ophthalmology 1995;102:1020-1025.
3. Järplid B, Schantz B. Rejection of skin and conjunctival allografts in the dog after prolonged graft survival.
Acta Chir Scand 1973;139:517-521.
4. Obel N, Schantz B. Transplantation of allogeneic conjunctiva as a complement to allogeneic skin grafting when studying immunosuppressive procedures in the dog.
Acta Chir Scand 1972;138:21-24.
5. Nussenblatt RB, Whitcup SM, Palestine AG. Uveiti. 1996. 2nd ed. St.Louis: Mosby; p. 106-122.
6. Dios E, Herreras JM, Mayo A, Blanco G. Efficacy of systemic cyclosporine A and amniotic membrane on rabbit conjunctival limbal allograft rejection.
Cornea 2005;24:182-188.
7. Kwon YS, Kim JC. Inhibition of corneal neovascularization by rapamycin.
Exp Mol Med 2006;38:173-179.
8. Kwon YS, Hong HS, Kim JC, et al. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo.
Invest Ophthalmol Vis Sci 2005;46:454-460.
9. Ebrahem Q, Minamoto A, Hoppe G, et al. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors.
Invest Ophthalmol Vis Sci 2006;47:4935-4941.
10. Benelli U, Ross JR, Nardi M, Klintworth GK. Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.
Invest Ophthalmol Vis Sci 1997;38:274-282.
11. De Saint Jean M, Baudouin C, Di Nolfo M, et al. Comparison of morphological and functional characteristics of primary-cultured human conjunctival epithelium and of Wong-Kilbourne derivative of Chang conjunctival cell line.
Exp Eye Res 2004;78:257-274.
12. Bell TA, Hunnisett AG. Cyclosporin A: tissue levels following topical and systemic administration to rabbits.
Br J Ophthalmol 1986;70:852-855.
13. Wiederholt M, Kossendrup D, Schulz W, Hoffmann F. Pharmacokinetic of topical cyclosporin A in the rabbit eye.
Invest Ophthalmol Vis Sci 1986;27:519-524.
14. Kaswan RL. Intraocular penetration of topically applied cyclosporine.
Transplant Proc 1988;20:650-655.
15. Stamer L, Bohnke M, Vogelberg K, Arndt R. Tissue levels of locally applied cyclosporin A in the rabbit eye.
Fortschr Ophthalmol 1989;86:540-542.
16. Mosteller MW, Gebhardt BM, Hamilton AM, Kaufman HE. Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum.
Arch Ophthalmol 1985;103:101-102.
17. Okada K, Sakata H, Minamoto A, Fujihara M. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats.
Ophthalmologica 1996;210:175-179.
18. Benelli U, Lepri A, Del Tacca M, Nardi M. FK-506 delays corneal graft rejection in a model of corneal xenotransplantation.
J Ocul Pharmacol Ther 1996;12:425-431.
19. Hikita N, Chan CC, Whitcup SM, et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat.
Curr Eye Res 1995;14:209-214.
20. Hikita N, Lopez JS, Chan CC, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats.
Invest Ophthalmol Vis Sci 1997;38:901-909.
21. Ang LP, Tan DT, Beuerman RW, Lavker RM. Development of a conjunctival epithelial equivalent with improved proliferative properties using a multistep serumfree culture system.
Invest Ophthalmol Vis Sci 2004;45:1789-1795.
22. Ang LP, Tan DT, Phan TT, et al. The in vitro and in vivo proliferative capacity of serum-free cultivated human conjunctival epithelial cells.
Curr Eye Res 2004;28:307-317.
23. Meller D, Tseng SC. Conjunctival epithelial cell differentiation on amniotic membrane.
Invest Ophthalmol Vis Sci 1999;40:878-886.
24. Ang LP, Cheng ZY, Beuerman RW, et al. The development of a serum-free derived bioengineered conjunctival epithelial equivalent using an ultrathin poly (epsilon-caprolactone) membrane substrate.
Invest Ophthalmol Vis Sci 2006;47:105-112.
25. Ang LP, Tan DT. Autologous cultivated conjunctival transplantation for recurrent viral papillomata.
Am J Ophthalmol 2005;140:136-138.
26. Nishida K, Yamato M, Hayashida Y, et al. Functional bioengineered corneal epithelial sheet grafts from corneal stem cells expanded ex vivo on a temperature-responsive cell culture surface.
Transplantation 2004;77:379-385.
27. Adinolfi M, Akle CA, McColl I, et al. Expression of HLA antigens, β2-microglobulin and enzymes by human amniotic epithelial cells.
Nature 1982;295:325-327.
28. Akle CA, Adinolfi M, Welsh KI, et al. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers.
Lancet 1981;2:1003-1005.
29. Horan PK, Slezak SE. Stable cell membrane labelling.
Nature 1989;340:167-168.
30. Horan PK, Melnicoff MJ, Jensen BD, Slezak SE. Fluorescent cell labeling for in vivo and in vitro cell tracking.
Methods Cell Biol 1990;33:469-490.
31. Slezak SE, Horan PK. Fluorescent in vivo tracking of hematopoietic cells. Part I. Technical considerations.
Blood 1989;74:2172-2177.
32. Slezak SE, Muirhead KA. Radioactive cell membrane labelling.
Nature 1991;352:261-262.
33. Teare GF, Horan PK, Slezak SE, et al. Long-term tracking of lymphocytes in vivo: the migration of PKH-labeled lymphocytes.
Cell Immunol 1991;134:157-170.
34. Bertelmann E, Pleyer U. Immunomodulatory therapy in ophthalmology - is there a place for topical application?
Ophthalmologica 2004;218:359-367.
35. Claman HN. Corticosteroids as immunomodulators.
Ann N Y Acad Sci 1993;685:288-292.
36. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis. 1996. 2nd ed. St.Louis: Mosby; p. 99-106.
37. Olsen TW, Benegas NM, Joplin AC, et al. Rapamycin inhibits corneal allograft rejection and neovascularization.
Arch Ophthalmol 1994;112:1471-1475.
38. Ohia EO, Mancino M, Kulkarni PS. Effects of steroids and immunosuppressive drugs on endotoxin-uveitis in rabbits.
J Ocul Pharmacol 1992;8:295-307.
39. Roberge FG, Xu D, Chan CC, et al. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction.
Curr Eye Res 1993;12:197-203.
40. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.
Clin Biochem 2006;39:484-489.
41. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.
Clin Biochem 1998;31:335-340.
42. Garweg JG, Wegmann-Burns M, Goldberg D. Effects of daunorubicin, mitomycin C, azathiprine and cyclosporine A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines.
Graefes Arch Clin Exp Ophthalmol 2006;244:382-389.
43. Nelson JD, Cameron JD. In: Krachmer JH, Mannis MJ, Holland EJ, The Conjunctiva: anatomy and physiology. Cornea. 2005. v. 2. Philadelphia: Elsevier Mosby; chap. 3.